Paroxetine inhibited the relaxations induced by EFS in mice corpus cavernosum: Is it a NOS inhibition?

Fundamental and Clinical Pharmacology

Volumn 24, Issue 1, 2010, Pages 55-61

  Kadioglu, Mine ^a   Muci, Efnan ^a   Ozyavuz, Rasin ^a   Yaris, Ersin ^a   Kesim, Murat ^a   Kalyoncu, Nuri I ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Corpus cavernosum; Fluoxetine; NOS inhibition; Paroxetine; Selective serotonin reuptake inhibitors; Sertraline

Indexed keywords

ARGININE; ATROPINE; FLUOXETINE; N(G) NITRO DEXTRO ARGININE METHYL ESTER; N(G) NITROARGININE METHYL ESTER; NIFEDIPINE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; PAROXETINE; PHENYLEPHRINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CORPUS CAVERNOSUM; DEPRESSION; DRUG EFFECT; EJACULATION DISORDER; ELECTROSTIMULATION; ENZYME INHIBITION; MALE; MOUSE; NONHUMAN; PENIS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SMOOTH MUSCLE RELAXATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; FLUOXETINE; MALE; MICE; MICE, INBRED BALB C; MUSCLE RELAXATION; MUSCLE, SMOOTH; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PAROXETINE; PENIS; PHENYLEPHRINE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 74049140306     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00742.x     Document Type: Article

References (35)

1. Gregorian R.S., Golden K.A., Bahce A., Goodman C., Kwong W.J., Khan Z.M. Antidepressant-induced sexual dysfunction. Ann. Pharmacother. (2002) 36 1577 1589.
2. Kennedy S.H., Eisfeld B.S., Dickens S.E., Bacchiochi J.R., Bagby R.M. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J. Clin. Psychiatry (2000) 61 276 281.
3. Keoghane S.R., Sullivan M.E., Miller M.A. The aetiology, pathogenesis and management of priapism. BJU Int. (2002) 90 149 154.
4. Montejo A.L., Llorca G., Izquierdo J.A., Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry (2001) 62 10 21.
5. Woodrum S.T., Brown C.S. Management of SSRI-induced sexual dysfunction. Ann. Pharmacother. (1998) 32 1209 1215.
6. Kalyoncu N.I., Ozyavuz R., Karaoglu S. Sertraline inhibits the contractile responses to noradrenaline, KCl and electrical field stimulation of rat isolated vas deferens. J. Auton. Pharmacol. (1999) 19 365 369.
7. Ozyavuz R., Kalyoncu N.I., Karaoglu S. Long-term use of sertraline leads to alterations in contractility of rat isolated vas deferens. Urol. Res. (2004) 32 20 24.
8. Busch L., Wald M., Sterin-Borda L., Borda E. Fluoxetine modulates norepinephrine contractile effect on rat vas deferens. Pharmacol. Res. (2000) 41 39 45. (Pubitemid 30008935)
9. Yaris E., Kesim M., Kadioglu M., Kalyoncu N.I., Ulku C., Ozyavuz R. The effects of paroxetine on rat isolated vas deferens. Pharmacol. Res. (2003) 48 335 345.
10. Medina P., Segarra G., Ballester R. et al. Effects of antidepressants in adrenergic neurotransmission of human vas deferens. Urology (2000) 55 592 597.
11. Power-Smith P. Beneficial sexual side-effects from fluoxetine. Br. J. Psychiatry (1994) 164 249 250.
12. Bonnot O., Warot D., Cohen D. Priapism associated with sertraline. J. Am. Acad. Child Adolesc. Psychiatry (2007) 46 790 791.
13. Finkel M.S., Laghrissi-Thode F., Pollock B.G., Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol. Bull. (1996) 32 653 658.
14. Angulo J., Peiro C., Sanchez-Ferrer C.F. et al. Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue. Br. J. Pharmacol. (2001) 134 1190 1194.
15. Angulo J., Bischoff E., Gabancho S., Cuevas P., Saenz de Tejada I. Vardenafil reverses erectile dysfunction induced by paroxetine in rats. Int. J. Impot. Res. (2003) 15 90 93.
16. Andersson K.E. Pharmacology of penile erection. Pharmacol. Rev. (2001) 53 417 450.
17. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. (1991) 43 109 142.
18. Bode-Boger S.M., Muke J., Surdacki A., Brabant G., Boger R.H., Frolich J.C. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc. Med. (2003) 8 77 81.
19. Tugba Durlu N., Brading A.F. The effects of exogenous amino acids on the relaxant responses of pig urethral smooth muscle evoked by stimulation of the inhibitory nitrergic nerves. Pflugers Arch. (2005) 449 413 421.
20. Maarsingh H., Tio M.A., Zaagsma J., Meurs H. Arginase attenuates inhibitory nonadrenergic noncholinergic nerve-induced nitric oxide generation and airway smooth muscle relaxation. Respir. Res. (2005) 6 23.
21. Kim N.N., Christianson D.W., Traish A.M. Role of arginase in the male and female sexual arousal response. J. Nutr. (2004) 134 (Suppl. 10) 2873S 2879S.
22. Pickard R.S., Powell P.H., Zar M.A. Nitric oxide and cyclic GMP formation following relaxant nerve stimulation in isolated human corpus cavernosum. Br. J. Urol. (1995) 75 516 522.
23. Pickard R.S., Powell P.H., Zar M.A. The effect of inhibitors of nitric oxide biosynthesis and cyclic GMP formation on nerve-evoked relaxation of human cavernosal smooth muscle. Br. J. Pharmacol. (1991) 104 755 759.
24. Naylor A.M. Endogenous neurotransmitters mediating penile erection. Br. J. Urol. (1998) 81 424 431.
25. Ignarro L.J., Bush P.A., Buga G.M., Wood K.S., Fukuto J.M., Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem. Biophys. Res. Commun. (1990) 170 843 850.
26. Rajfer J., Aronson W.J., Bush P.A., Dorey F.J., Ignarro L.J. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med. (1992) 326 90 94.
27. Simonsen U., Garcia-Sacristan A., Prieto D. Penile arteries and erection. J. Vasc. Res. (2002) 39 283 303.
28. Loscalzo J. What we know and don't know about L-arginine and NO. Circulation (2000) 101 2126 2129.
29. Bourin M., Chue P., Guillon Y. Paroxetine: a review. CNS. Drug. Rev. (2001) 7 25 47.
30. Vemulapalli S., Kurowski S. Phentolamine mesylate relaxes rabbit corpus cavernosum by a nonadrenergic, noncholinergic mechanism. Fundam. Clin. Pharmacol. (2001) 15 1 7.
31. Ahn G.J., Kang K.K., Kim D.S. et al. DA-8159 reverses selective serotonin reuptake inhibitor-induced erectile dysfunction in rats. Urology (2005) 65 202 207.
32. Frye C.A., Rhodes M.E. Zaprinast, a phosphodiesterase 5 inhibitor, overcomes sexual dysfunction produced by fluoxetine, a selective serotonin reuptake inhibitor in hamsters. Neuropsychopharmacology (2003) 28 310 316.
33. Nurnberg H.G., Duttagupta S. Economic analysis of sildenafil citrate (Viagra) add-on to treat erectile dysfunction associated with selective serotonin reuptake inhibitor use. Am J Ther. (2004) 11 9 12.
34. Goodnick P.J., Goldstein B.J. Selective serotonin reuptake inhibitors in affective disorders - I. Basic pharmacology. J Psychopharmacol. (1998) 12 (Suppl. B) 5 20.
35. Finley P.R. Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann. Pharmacother. (1994) 28 1359 1369.